A Study of HDC/IL-2 Treatment in Chronic Myelomonocytic Leukemia (CMML)

NCT03040401 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

UNKNOWN

Status

15

Enrollment

OTHER_GOV

Sponsor class

Conditions

Leukemia, Myelomonocytic, Chronic

Interventions

DRUG: Cohort 1, Ceplene® and Proleukin®
DRUG: Cohort 2, Ceplene® and Proleukin®
DRUG: Cohort 3, Ceplene® and Proleukin®

Sponsor

Vastra Gotaland Region

Collaborators

[object Object]
[object Object]
[object Object]